2024-03-25 05:22:18 ET
Summary
- ARK Genomic Revolution ETF warrants a hold rating due to multiple roadblocks preventing solid returns, including underdeveloped technology, legal hurdles, and unresolved ethical dilemmas.
- ARKG has a relatively high expense ratio with no dividend yield, and its performance has significantly underperformed the S&P 500 Index.
- The fund's holdings are concentrated in the healthcare sector, with little overlap with other peer genomics-related funds.
Investment Thesis
Read the full article on Seeking Alpha
For further details see:
ARKG: Massive Potential, But Not Worth The Risk Yet For These 3 Reasons